Navigation Links
MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
Date:8/10/2012

WOONSOCKET, R.I., Aug. 10, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the updated preclinical research results for MCT-465 and MCT-485.  MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines.  MCT-485 induced robust TNFalpha and some IL-6 expression.  In contrast, MCT-465 showed no cytotoxicity or anti-proliferative effect.  The research results support further mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as novel therapeutic agents as a treatment for hepatocellular carcinoma and other cancers.

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and a leading cause of cancer death.  Current pharmacological approaches for the treatment of human HCC are very limited in their efficacy.  A potential role for noncoding double stranded RNAs such as MCT-465 and MCT-485 in the control of tumors has recently emerged in a variety of models with recognition of their ability to stimulate an immune response or directly affect cell death.

According to the National Cancer Institute, annually in the United States there are approximately 21,400 new cases of primary liver cancer and intrahepatic bile duct cancer, and approximately 18,400 of those cases resulted in death.  Primary liver cancer, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world with more than 1 million new cases diagnosed each year.  Primary liver cancer is rarely discovered early, and often does not respond to current treatment.

About MCT-465 and MCT-485

MCT-465 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented TLR3 signaling technology.  MC
'/>"/>

SOURCE MultiCell Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CanCHEW Bio-Technologies, a Medical Marijuana Inc. Product, Dr. George Anastassov Appeared on Small Cap Voice Internet Radio Program To Discuss The CanCHEW Advantage
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. Life Technologies Announces Second Quarter 2012 Results
4. Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
5. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
6. Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa
7. Life Technologies Develops Simplified SAME-DAY STEC Solution for Detecting Multiple Strains of E. coli in Ground Beef
8. Ellman International Launches Multi-stage Growth Plan With Acquisition Of Sandstone Medical Technologies
9. Lifeline Biotechnologies First Warning Systems
10. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
11. Acquisition of Navigenics Expands Life Technologies Capabilities in Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... July 11, 2014 ... Safety & Health Expo 2014 were a ... to London , plus ... exhibition.          (Logo: ... )      (Photo: ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Aug. 17, 2011 Reportlinker.com announces that ... in its catalogue: Levosimendan ... http://www.reportlinker.com/p0483048/Levosimendan---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Eliminate unnecessary ... patent information. Pipeline Developer is ...
... 16, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with ... The Journal of the American Medical Association ( ... resulted in significant and sustained reductions in uric acid ...
Cached Medicine Technology:Levosimendan - Comprehensive Patent Search 2Levosimendan - Comprehensive Patent Search 3Levosimendan - Comprehensive Patent Search 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:7/11/2014)... City, UT (PRWEB) July 11, 2014 WWTrek ... work at the Kilimanjaro Kids Community in Tanzania. Opened in ... goats, 150 chickens, and two cows. HOP Founder, Dean Cardinale, ... education for some of the orphaned children he encountered while ... HOP Team visited the children, who have all made astounding ...
(Date:7/11/2014)... Francisco shows that an "expressive therapy" group intervention ... with HIV disclose their health status and improves ... quality of their relationships., "Medication alone is totally ... Machtinger, MD, director of the Women,s HIV Program ... are on effective antiretroviral therapy but far too ...
(Date:7/11/2014)... July 11, 2014 Recently, iFitDress.com, a ... occasion outfits, has released its new collection of ... the company has announced that all these beautiful items ... The deadline of the special offer is July 22. ... major officials pay close attention to customer satisfaction. On ...
(Date:7/11/2014)... July 11, 2014 Organic Crop ... being launched into the limelight over the past decade. ... was once considered to be an alternative food eaten ... are now purchasing organic food.” Organic crop farmers have ... vegetables, grains, nuts and herbs over the past five ...
(Date:7/11/2014)... personalized medicine may be just around the corner, thanks ... Yu and scientists at Massachusetts General Hospital and Harvard ... Science , Yu and her colleagues report how ... streams of six patients. Some of these deadly cancer ... and establish secondary tumors in vital organs such as ...
Breaking Medicine News(10 mins):Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4
... Beneficial bacteria found in healthy women help to reduce the ... more difficult for the virus to spread, boosting the possibility ... against HIV. , The findings come from physicians and scientists ... Medical Center, who worked together in an effort to learn ...
... a national healthcare,management and technology company, has renewed ... West Virginia to provide Revenue Cycle,Management (RCM), ASP ... physician groups., St. Mary,s Medical Center provides ... in several specialties. MED3OOO,s subsidiary,MED3OOO Health Solutions of ...
... CYT, MONTREAL, Feb. 7 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), will,hold a ... (Eastern Time) on Thursday, February 14, 2008. The Company,will report its results ... 14., DATE: ... ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... announced today that its CareCentrix(R),ancillary care benefit management ... homecare contract with CIGNA HealthCare, which will,provide for ... CIGNA,members through January 31, 2011. The extension amends ...
... employee benefit Increasing animal obesity, more and better pet care ... ... The insurance industry is,going to the dogs ... and cats., Officials ... friends and the growth trends for pet insurance are,only going to accelerate ...
... close ties with parents is obviously good for preschoolers, ... the preschoolers are better able to control their own ... , Thats the finding of a new study conducted ... in the January/February 2008 issue of the journal Child ...
Cached Medicine News:Health News:'Good bacteria' in women give clues for slowing HIV transmission 2Health News:'Good bacteria' in women give clues for slowing HIV transmission 3Health News:St. Mary's Medical Center Renews RCM & Technology With MED3000 2Health News:CryoCath to Hold First Quarter 2008 Conference Call and Webcast 2Health News:Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011 2Health News:Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011 3Health News:PetFirst: Pet Insurance To Be More Popular in 2008 2Health News:Close ties between parents and babies yield benefits for preschoolers 2
... peripheral nerve stimulator from B. Braun Medical. ... nerve stimulator functionality for over 10 years. ... available, a unique, under-the-glove hand held remote ... Dig. It allows the anesthesia provider operating ...
... Control allows hands-free operation in nerve locator ... 5.0 mA) with SoloStim provides a wide ... control when close to nerve., ,Supported ... block products, including the clinically proven ProBloc™ ...
... your investment., ,The Centiva/5 Critical Care Ventilator ... demands of the critical care environment. The Centiva ... combining a compact size with high levels of ... space around the patients bed and allows you ...
... Mesh Elastic is a lightweight and large pore ... mesh is able to adapt to all movements ... honeycomb like structure with the large pores enables ... The mesh is ideal for incisional hernia repair ...
Medicine Products: